MedTrace Logo

Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection

NCT00455806 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2007-04-04

No results posted yet for this study

Summary

Successful H. pylori eradication therapy remains a challenge in medical practice. Despite promising data for first-line, second-line and rescue treatment options based on clinical trials as well as guidelines and expert recommendations, success rates can often not be reproduced in general practice. Rescue options for patients with failed initial or second-line therapy are definitely needed. The new fluoroquinolone moxifloxacin may represent an effective and save treatment option (in combination with a PPI and amoxicillin) for rescue therapy of H- pylori positive patients.However, optimal duration of therapy (7-day course vs 14-day course) has to be determined

Conditions

  • Helicobacter Pylori Infection
  • Chronic Gastritis

Interventions

DRUG

esomeprazole

DRUG

moxifloxacin

DRUG

amoxicillin

Sponsors & Collaborators

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Stephan Miehlke, MD, PhD · Medical Department I, Gastroenterology, Universityhospital, Technical University Dresden

  • Norbert Lehn, MD, PhD · Institue for Medical Microbiology, University of Regensburg

  • Enno Jacobs, MD, PhD · Institute for Medical Microbiology, Technical University of Dresden

  • Manfred Stolte, MD, PhD · Institute for Pathology, Klinikum Bayreuth

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Completion
2008-02-29

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00455806 on ClinicalTrials.gov